The development of anticholinergics in the management of COPD by Scullion, Jane E
International Journal of COPD 2007:2(1) 33–40
© 2007 Dove Medical Press Limited.  All rights reserved
33
REVIEW
The development of anticholinergics in the 
management of COPD
Jane E Scullion
University Hospitals of Leicester 
Glenfield Site, Institute for Lung 
Health, Leicester; Department of 
General Practice and Primary Care, 
Aberdeen University, Aberdeen, UK
Correspondence: Jane E Scullion
Tel +44 11 6256 3949
Fax +44 11 6236 7768
Email jane.scullion@uhl-tr.nhs.uk
Abstract: Anticholinergics have been used to treat obstructive respiratory disease for many 
years from historical preparations of the deadly nightshade genus, to the more recent develop-
ments of ipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction 
has focused on achieving maximal airway function through bronchodilators. Of the two main 
bronchodilators, beta2-agonists are often the ﬁ  rst treatment choice although there is evidence of 
equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive 
pulmonary disease (COPD). The following review looks at the background of anticholinergics, 
their pharmacological properties, and the evidence for use with suggestions for their place in 
the treatment of COPD.
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Background
A combination of genetic, constitutional, familial, behavioral, sociodemographic, and 
environmental factors predispose patients to chronic obstructive pulmonary disease 
(COPD), with cigarette smoking the most common cause (BTS 1997; NCCCC 2004). 
These factors damage the airways and impair the defense and repair mechanisms 
(Turato et al 2002), leading to structural narrowing of the airways, which is predomi-
nantly irreversible due to a combination of ﬁ  brosis, mucus hyperplasia, and alterations 
in vagal bronchomotor tone. Loss of elastic recoil in the lung caused by parenchymal 
destruction characterizes the emphysemic component. Increased resistance in the 
airways as a result of airway inﬂ  ammation increases the thickness of the airway walls, 
and narrows the airways, which reduces the driving pressure; the obstructive element 
(Turato et al 2002). There is also excessive mucus secretion increased by goblet cell 
proliferation; the bronchitic component. For patients this means declining lung function, 
breathlessness and other symptoms, exacerbations, and reductions in health status or 
health related quality of life (HRQoL).
Few treatments have been manufactured specifically for patients with 
COPD. Treatments evolved from asthma treatments through a tendency to treat the 
two diseases as one, a misunderstanding of the pathogenesis of the diseases and a 
nihilistic view of COPD with treatment considered as palliative rather than curative or 
restorative. This was reinforced by insufﬁ  cient evidence to conclude that any speciﬁ  c 
pharmacotherapeutic agents signiﬁ  cantly altered the outcome of the disease process 
(Halpin 2001). 
A growing evidence base now supports the use of bronchodilators in COPD 
to improve function, exercise tolerance and health status (Crockett 2000; 
Halpin 2001; NIHLBI 2001; NCCCC 2004). Inhaled therapy is the cornerstone 
of treatment comprising anticholinergics which relax airway smooth muscle by International Journal of COPD 2007:2(1) 34
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blocking cholinergic tone (the primary reversible component 
in COPD), and beta2-agonists which are nonspeciﬁ  c func-
tional bronchodilators that work via the sympathetic pathway 
(Cooper and Tashkin 2005). There is increased evidence of 
a greater response to anticholinergics than beta2-agonists 
(Barnes 1999; Cooper and Tashkin 2005). This review dis-
cusses the history of anticholinergic therapy, pharmacology, 
dynamics and kinetics, clinical efﬁ  cacy, and tolerability with 
conclusions and suggestions of place in therapy.
A brief history of anticholinergics
Anticholinergics originate from botanical preparations of the 
deadly nightshade family (Solanaceae) used for hundreds 
of years in many cultures worldwide (Chapman et al 2006). 
Datura is a genus of the Solanaceae family and it grows 
worldwide (Chapman et al 2006). The burning roots, stems, 
and seeds of these plants release an aerosol of potent alka-
loids, one of which is the antimuscarin compound, atropine. 
It was the inhalation of this medicinal smoke that was a 
treatment for obstructive airways disease for many centuries 
(Chapman et al 2006). In addition to atropine other alkaloids, 
including scopolamine and hyoscyamine, are released with 
additional effects including intoxication, hallucinations, and 
poisoning. Derived from atropine-containing plants, anticho-
linergics work by inhibiting the parasympathetic–cholinergic 
system (Gross 1995). Brewis (1990) suggests that it was 
the Egyptians who ﬁ  rst used anticholinergics in respiratory 
medicine and there is evidence of their use in Ayurvedic 
medicine in the 17th century and by the Greek physicians 
of Hippocrates’ era (Gandevia 1975).
In Britain, Sims recorded the ﬁ  rst use of Datura to treat 
asthma in 1802 (Gandevia 1975) and although its use was 
controversial, it became a popular over the counter medication 
taken in the form of a cigarette or pipe tobacco. The amount 
of atropine reaching the lungs was dependent on deep inhala-
tion with a small amount absorbed across the oral mucosa or 
swallowed and absorbed via the gastrointestinal tract. 
Atropine based agents became the standard bronchodila-
tors for respiratory disorders however, the unpleasant side 
effects of the emerging adrenergic drugs in the 1920s and 
theophyllines in the next decade led to a decline in the use of 
these agents for many years (Chapman et al 2006).
Following studies describing the role of the 
parasympathetic system in controlling the calibre of the 
airways there was an emerging interest in anticholinergic 
therapies (Widdicombe 1966; Gandevia 1975; Barnes 
1986). This led to the recognition that inhibiting the 
parasympathetic-cholinergic system could be an alternative 
therapeutic approach to improving airﬂ  ow, and revived an 
interest in using anticholinergics. Available anticholinergics 
include ipratropium bromide, oxitropium, and tiotropium, 
which work by blocking the muscarinic receptors for the 
neurotransmitter acetylcholine released from cholinergic 
nerve endings in the airways.
Pharmacology, dynamics, 
and kinetics
All cells communicate by chemical and electrical signaling. 
Although a complex process, the relevant features of intercel-
lular signaling are achieved by the secretion of a chemical 
molecule by the transmitting cell. The signaling molecule, 
known as a ligand, travels to the receiving cell, which recog-
nizes the ligands that are relevant to it and binds the cell with 
a reversible bond. The process of chemical binding changes 
the receptor protein activating it, causing the appropriate 
alteration in cell function and producing an appropriate, 
graded response. Many drugs mimic endogenous chemical 
signals by binding as ligands at receptors on cell membranes. 
Those drugs that bind to such recognition sites without caus-
ing a response, but which prevent access to the site by the 
natural agonist are known as antagonists or receptor blockers. 
The speed with which the reversible bond breaks down gives 
the duration of a drug’s action.
Anticholinergics are antagonists of muscarinic receptors 
and, in therapeutic use, have no other signiﬁ  cant pharma-
cological effects (Barnes 2004). In animals and humans 
there is a small degree of resting bronchomotor tone due to 
tonic vagal nerve impulses that release acetylcholine in the 
vicinity of airway smooth muscle (Barnes 2004). Anticho-
linergic drugs can block this release. Acetylcholine may also 
be released from other cells apart from nerve cells, but the 
mechanism for this is not well documented. The synthesis of 
acetylcholine in epithelial cells is increased by inﬂ  ammatory 
stimuli increasing the expression of choline acetyltransferase 
that may contribute to cholinergic effects in airways disease, 
Muscarinic receptors are expressed in the airway smooth 
muscle of small airways not innervated by cholinergic nerves, 
but may be an important mechanism of airway narrowing in 
peripheral airways (Barnes 2004). Anticholinergics therefore 
inhibit reﬂ  ex cholinergic bronchoconstriction and have no 
direct blocking effect on inﬂ  ammatory mediators such a 
histamine and leukotrines in bronchial smooth muscle.
There are several subtypes of muscarinic receptors, three 
of these found in the airways have different functioning International Journal of COPD 2007:2(1) 35
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effects (Barnes 1986, 1993). These receptors principally M1, 
M2, and M3 are predominantly localized in the smooth muscle 
of the airways, although higher in density in the proximal 
airways and in high density to the submucosal glands (Barnes 
1986, 1993). Anticholinergic drugs work by blocking the 
receptors (muscarinic receptors) from the neurotransmitter 
acetylcholine, which is released from cholinergic nerve end-
ings in the airways.
M1 receptors
M1 receptors are localized to parasympathetic ganglia in 
the airways, where they appear to function as regulators of 
ganglionic transmission. Preganglionic nerves release acetyl-
choline, which acts on the nicotinic receptors on ganglionic 
cells to activate postganglionic nerves. Only a proportion 
of preganglionic signals are translated into postganglionic 
impulses. M1 receptors facilitate transmission through these 
ganglia and enhance cholinergic reﬂ  ex bronchoconstriction 
(Celli 2004).
M2 receptors
M2 receptors are located on the ends of cholinergic nerve end-
ings and act as feedback inhibitors of acetylcholine release 
from the nerve. Blocking these receptors leads to an increased 
release of acetylcholine and increased bronchoconstrictor 
response to cholinergic nerve stimulation. Ipratropium and 
oxitropium bromide are nonselective blockers and therefore 
block the M2 receptors, which increases acetylcholine re-
lease and reduces the degree of blockade or the duration of 
action on the M3 receptors. These possibly explain reported 
paradoxical bronchoconstriction after the use of ipratropium 
bromide (Celli 2004).
M3 receptors
The M3 receptors mediate the bronchoconstrictor response 
to cholinergic nerve stimulation and cholinergic agonists. 
Tiotropium alone of the anticholinergics exhibits kinetic 
receptor subtype selectivity in which the dissociation from 
M3 receptors is approximately 35 hours thus giving sus-
tained bronchodilation with a once daily dosing (Disse 
et al 1999).
Ipratropium, oxitropium, and tiotropium are quaternary 
ammonium compounds, which effectively means that they 
are electrically charged and as such are not absorbed from the 
gastrointestinal tract and do not pass the blood–brain barrier. 
This reduces any potential anticholinergic side effects. As the 
vagal tone on the airway appears to be the major reversible 
element in COPD, even a small effect on vagal tone through 
bronchodilatation may beneﬁ  t the patient (Gross 1993). 
Anticholinergics are effective bronchodilators in COPD 
where the effects of bronchoconstriction are inﬂ  ated by air-
ways resistance in narrowed airways. Cholinergic nerves also 
encourage mucus secretion so anticholinergics may be seen 
to be useful in reducing airways mucus secretion although 
this has only be shown in one study with oxitropium (Coe 
and Barnes 1986).
Anticholinergic bronchodilators have also been docu-
mented as having a beneﬁ  cial effect on the quality of patients’ 
sleep in asthma (Coe and Barnes 1986). 
The role of anticholinergics 
in COPD
Achievement of maximal airway function through regular 
use at the maximum tolerated levels of bronchodilators. im-
proves symptoms and exercise tolerance (Gross 1993; Barnes 
2004; Pauwels et al 2001; NCCCC 2004). The short-acting 
bronchodilators, ipratropium and oxitropium, are slower in 
onset for bronchodilatation than the beta2-agonists, but have 
a sustained mode of action and may be considered at least as 
effective and possibly more so in COPD (Table 1) (Chapman 
1991). Guidelines advocate that, for severe COPD, combi-
nation therapies with regular β2-agonist and anticholinergic 
therapy should be given (Gross 1993; Pauwels et al 2001; 
Barnes 2004; NCCCC 2004).
Ipratropium bromide 
Ipratropium bromide was introduced in 1974 and made it 
possible to give local anticholinergic effects to the lung 
whilst avoiding the systemic side effects of atropine due to 
its poor absorbtion (Chapman 1993). Ipratopium has been 
studied in patients with acute exacerbations of COPD either 
in an inhaled or nebulized form. Ipratropium starts to act 
within 15–30 minutes, but maximal bronchodilatation may 
take up to 90 minutes in COPD (Rebuck et al 1987; Karpal 
et al 1990). The duration of action is approximately six hours 
so in comparison with beta2-agonists it has a slower onset 
of action, probably a longer duration of action, and does not 
cause tachyphylaxis or the drop in oxygenation that can occur 
with beta2-agonists (Karpal 1993). This fall in oxygenation 
could be due to an initial worsening of ventilation-perfusion 
mismatch resulting from pulmonary vasodilatation and/or 
increased cardiac output with beta2-agonist use or it may 
be that anticholinergic agents have less effect on pulmonary 
circulation, are not systemically absorbed, and therefore do International Journal of COPD 2007:2(1) 36
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not cause deterioration in blood oxygen tension (Gross and 
Bankwala 1987). Oral anticholinergics are not a treatment 
option for COPD because of unacceptable side effects, 
whereas inhaled anticholinergics have virtually no systemic 
absorption.
Oxitropium bromide 
Oxitropium bromide became available in the early 1990s 
and was promoted as having a longer mode of action than 
ipratropium bromide. However, a review of studies by Hardy 
and colleagues (1992) concluded that there was little evidence 
of this longer mode of action using equivalent doses. The 
published studies were small and either did not show any 
signiﬁ  cant differences or were in asthmatic patients (Peel 
et al 1984; Ikeda et al 1995). Oxitropium use in the UK was 
minimal and it is no longer on formulary. 
Tiotropium bromide 
Tiotropium bromide is a once-daily, long-acting 
anticholinergic with high potency as a selective antagonist 
at the muscarinic acetylcholine receptors and with kinetic 
selectivity (Barnes 2000; Littner et al 2000). Tiotropium 
rapidly dissociates from the autoinhibitory M2 receptors, 
but slowly dissociates from M1 and M3 receptors, which 
mediate acetycholine-mediated bronchoconstriction and 
mucus secretion. This increased duration of binding at the 
M3 receptors results in prolonged bronchodilatation, allowing 
a once-daily dose compared with the three to four doses per 
day previously necessary with ipratropium (Barnes 2000; 
Littner et al 2000). Tiotropium is rapidly absorbed into the 
circulation with a peak plasma concentration within 5 minutes 
followed by a rapid fall within an hour to a steady state and 
a terminal half life of 5–6 days that is independent of dose. 
Calculations are that this concentration would occupy <5% of 
muscarinic receptors and would account for the low incidence 
of side effects (Barnes 2000; Littner et al 2000).
Tiotropium has a good safety proﬁ  le with relatively few 
side effects. Those documented effects are mainly oral prob-
lems, particularly an unpleasant taste, and potential problems 
are urinary problems and glaucoma. 
Tiotropium bromide is delivered to the lungs by inhala-
tion through a device known as the Spiriva® HandiHaler® 
(Boehringer Ingelheim Pharmaceuticals, Inc, Ridgeﬁ  eld, CT, 
USA) (Figure 1). a device developed speciﬁ  cally for use by 
Table 1 The beta2-agonists and anticholinergics
Medication  Mode of action  Reported side effects
Salbutamol  Rapid onset of action  Fine tremor
  Duration of action 3–5 hours  Headache
Terbutaline  Rapid onset of action  Nervous tension
  Duration of action 3–5 hours  Muscle cramps
Salmeterol  Maximum effect after 40 minutes  Tachycardia
  Duration of action 12 hours  Arrythmias
Formoterol  Rapid onset of action  Paradoxical bronchospasm
  Duration of action 12 hours+  Hypokalemia
   Urticaria
   Angioedema
    Sleep and behaviour disturbance in children
    Fall in oxygen saturations
Ipratropium  Maximum effect after 15–90 minutes  Dry mouth
   Nausea
  Duration of action 3–6 hours  Headache
Oxitropium  Maximum effect after 30–60 minutes  Urinary retention
   Blurred  vision
  Duration of action 6 hours*  Glaucoma risk
  (*little evidence of longer duration than 6 hours)  Paradoxical bronchospasm
Tiotropium  Onset of action  Tachycardia and atrial ﬁ  brillation 
  Duration of action 35 hours  has been reportedInternational Journal of COPD 2007:2(1) 37
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patients with COPD and tested at variable inspiratory ﬂ  ow 
rates, which enables use by patients at all levels of disease 
severity. The device delivers individual doses by means of 
a capsule inserted into the device that is then activated and 
subsequently inhaled. It is a once daily dose, which may be 
beneﬁ  cial in terms of adherence with treatment.
Clinical ﬁ  ndings
In published clinical trials, anticholinergics have been compared 
with placebo, the beta2-agonists, and each other. The relevant 
ﬁ  ndings from the trials relate to improvements in spirometric 
measurements, breathlessness, exacerbation rates, HRQoL, and 
exercise tolerance during rehabilitation. More recently long 
acting beta2-agonists and anticholinergic have been combined 
to look at effectiveness (Di Marco et al 2006).
Spirometric measurements
In COPD bronchodilators are the mainstay of treatment and 
clinical trials have been based on  demonstration of improve-
ments in lung function although this is by deﬁ  nition relatively 
ﬁ  xed in this disease.
In a review of seven clinical trials comparing ipratropium 
with a beta2-agonist long-term therapy with ipratropium 
improved baseline forced expiratory volume at one second 
(FEV1) whilst the beta2-agonist did not (Rennard et al 1996). 
For tiotropium, improvements in trough FEV1 by 12% over 
baseline in comparison with placebo were found (Casaburi 
et al 2002). Trough forced vital capacity (FVC) and morning 
and evening peak expiratory ﬂ  ow rate (PEFR) also improved 
(Casaburi et al 2002; Serby 2002). Bronchodilation was also 
consistent over the year, which showed that patients did not 
become resistant to the effects (Casaburi et al 2002).
Compared with ipratropium, tiotropium improved 
spirometric values (Serby 2002). Trough FEV1 improved 
from baseline by 120 ml with tiotropium, and declined by 
30 ml with ipratropium after 1 year, implying that the effects 
of tiotropium were sustained (Serby 2002).
In comparison with salmeterol, tiotropium improved 
lung function measured over 12 hours and was sustained 
at 6 months (Donahue et al 2002). However the combined 
studies of Donohue and colleagues (2002) and Witek and 
Mahler (2002) looking at spirometry at 13 and 3 hours in 
comparison with salmeterol, did not report any spirometric 
outcomes. This supports the ﬁ  xed nature of lung function 
in COPD.
Trough FEV1 has been criticized as a measure in 
tiotropium trials. Baseline FEV1 was calculated as the 
mean of two readings measured in the morning of the 
randomization visit prior to the administration of the study 
medication. Trough FEV1 is the predose FEV1 deﬁ  ned as the 
mean of the two FEV1 readings taken at one hour and at ﬁ  ve 
minutes before administration of the study medication. The 
trough FEV1 response was deﬁ  ned as the difference between 
baseline and trough FEV1 and was the primary bronchodilator 
efﬁ  cacy endpoint in the studies. As tiotropium has a sustained 
action of around 35 hours this would inﬂ  uence measurements 
taken at 24 hours.
Forced expiratory volume at one second measurements do 
not correlate well with the symptoms experienced by patients 
and may be at best a surrogate measure for many of the goals 
of COPD management. Patients are individual and some 
endure a substantial loss of lung function with little in the 
way of symptoms or impact on their lives. At the other end of 
the scale, there are patients sensitive to small changes in lung 
Figure 1 The Spiriva® HandiHaler® (Boehringer Ingelheim Pharmaceuticals, Inc, Ridgeﬁ  eld, CT, USA). International Journal of COPD 2007:2(1) 38
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function that will report symptoms and impact on quality of 
life at an earlier level of physiological functioning. 
Breathlessness
Patients with COPD report a number of symptoms, princi-
pally breathlessness. In severe COPD, breathlessness occurs 
on minimal exertion and when undertaking simple everyday 
tasks. Increasing breathlessness often encourages the patient 
to seek medical help, although this is often at a late stage of 
the disease by which time the damage is largely irreversible 
(BTS 1997; Pauwels et al 2001; NCCCC 2004). Patients 
often report disturbed breathing patterns, particularly at night 
when lung function is suboptimal. Increased vagal tone is the 
likely reason for an increase in nocturnal bronchoconstriction 
(Coe and Barnes 1986).
Breathlessness appears to be linked physiologically to 
dynamic hyperinﬂ  ation in the lungs. In patients, dynamic 
hyperinﬂ  ation means an increased residual volume in the 
lung; inspiratory capacity (IC) is reduced and increasing 
the tidal volume is ineffective at reducing dynamic 
hyperinﬂ  ation. Lung hyperinﬂ  ation will inﬂ  uence inspiratory 
muscle function, breathing patterns, the ability of the body to 
eliminate carbon dioxide, and the feelings of breathlessness 
(O’Donnell et al 2004).
Breathlessness is a useful outcome measure in clinical 
trials. Tiotropium in comparison with placebo, improved 
breathlessness measured on the baseline dyspnea index (BDI) 
and on the transitional dyspnea index (TDI) in comparison 
with ipratopium (Serby 2002; Vincken et al 2006). The 
tiotropium group used less salbutamol, which may be a proxy 
measure of reduced breathlessness (Casaburi et al 2002). The 
BDI and TDI are validated multidimensional measurements 
based on activities of daily living of patients and provide data 
on the progression of disease; these instruments can be used 
to evaluate symptoms, which are important in clinical trials 
(Witek and Mahler 2002).
Exacerbations
Patients report symptoms including cough, sputum production, 
wheeze, and chest tightness, and these are often linked to a 
periodic worsening of symptoms, known as exacerbations that 
vary in severity and duration. This worsening of symptoms 
regularly leads to general practitioner consultations and frequently 
to hospitalization, and has a detrimental effect on lung function, 
symptoms, general well-being, and quality of life (Wedzicha 
et al 2001). Reducing exacerbation rates is an important outcome 
measure in disease management (Dusser et al 2006).
Exacerbations in the tiotropium studies were deﬁ  ned as 
changes in cough, wheeze, sputum production, and dyspnea 
lasting more than 3 days. When compared with placebo 
and ipratropium, tiotropium bromide delivered a signiﬁ  cant 
reduction in exacerbations (Casaburi et al 2002; Vincken 
et al 2006). In comparison with placebo, tiotropium reduced 
exacerbations by 20%, delayed the onset of exacerbations, 
reduced hospitalizations by 47% and demonstrated a 50% 
reduction in actual days in hospital (Casaburi et al 2002). 
Tiotropium also reduced exacerbations by 24% at 1 year 
hospital in comparison with placebo (O’Donnell et al 2004).  
When compared with placebo, tiotropium reduced exacer-
bations, associated healthcare resource use, and improved 
airﬂ  ow over a year (Dusser et al 2006).
A recent meta-analysis pooling data from 22 studies that 
compared anticholinergics and beta2-agonists concluded that 
inhaled anticholinergics, but not beta2-agonists signiﬁ  cantly 
reduced severe exacerbations and respiratory deaths in COPD 
patients and that the beta2-agonists were associated with a 
greater risk of death and possible worsening disease control 
(Salpeter et al 2006). 
Rees (2002) suggests that in the Vincken (2006) study 
nine patients need to be treated with tiotropium rather than 
ipratropium for I year to prevent one exacerbation and 23 
patients treated to prevent one hospital admission, although 
patients had low exacerbation rates overall. In the Casaburi 
study seven patients needed to be treated to keep one patient 
exacerbation free and 26 to prevent one hospital admission 
(Rees 2002). The cost-beneﬁ  t analysis of these studies re-
quires further evaluation and low overall exacerbation rates 
may not reﬂ  ect what currently happens in practice.
Whilst exacerbations and mortality are useful clinical 
outcomes, exacerbation data from clinical trials may vary 
in the deﬁ  nition of an exacerbation, which can inﬂ  uence the 
interpretation of the clinical ﬁ  ndings. The ﬁ  ndings will also 
be dependent on the average number of exacerbations of 
patients entering the trials. 
Health-related quality of life
One of the goals of COPD management is to improve health 
status and there are many published and well validated instru-
ments for measuring this. It is important is that the authors 
of the tools specify what constitutes a meaningful outcome 
from using their measurements to allow for the signiﬁ  cance 
of the ﬁ  ndings to be evaluated.
Tiotropium when compared with placebo was reported 
as having a positive effect on HRQoL (Casaburi et al 2002; International Journal of COPD 2007:2(1) 39
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Serby 2002). In the Saint George’s Respiratory Questionnaire 
(SGRQ), there were improvements both in the total score and 
in the symptom, activity, and impact on life scores (Casaburi 
et al 2002). In comparison with ipratropium, both groups 
improved although tiotropium had a statistically signiﬁ  cant 
impact over ipratropium using the SGRQ, indicating that the 
HRQoL improved and this was still evident at 12 months so 
the effect was sustained (Vincken et al 2006). 
Exercise tolerance and pulmonary 
rehabilitation
In COPD, changes in IC, a surrogate measure for hyperinﬂ  a-
tion, correlate to patient-focused outcomes such as dyspnea 
on exercise. When tiotropium was compared with placebo, 
there was a positive effect on IC maintained over a 24 hour 
period (Celli et al 2003).
O’Donnell and colleagues (2004) tested the hypothesis 
that using tiiotropium would be associated with a sustained 
reduction in lung hyperinﬂ  ation improving exertional dys-
pnea and exercise performance. This randomized double-
blind placebo-controlled, parallel-group study compared 
tiotropium and placebo over 42 days of treatment and 
concluded tiotropium was associated with sustained reduc-
tions of lung hyperinﬂ  ation both at exercise and rest. They 
hypothesized that the resultant increases in IC permitted 
greater expansion of tidal volume and contributed to improve-
ments in both exertional dyspnea and exercise endurance. 
The study was seen as supporting the hypothesis that lung 
hyperinﬂ  ation, mechanical restriction, respiratory discom-
fort and exercise intolerance are closely related in COPD 
(O’Donnell et al 2004).
As exercise tolerance and the ability to undertake every-
day activities are often compromised in COPD, primarily due 
to dyspnea, any reduction in dyspnea will be an important 
treatment goal. Pulmonary rehabilitation has a proven beneﬁ  t 
in COPD showing improvements in exercise tolerance. Casa-
buri and colleagues (2005) tested the hypothesis that tiotro-
pium would be beneﬁ  cial in improving ventilatory mechanics 
and augment the exercise tolerance beneﬁ  ts of pulmonary 
rehabilitation. Tiotropium was compared with placebo over 
an eight week programme of pulmonary rehabilitation and 
improved endurance at a constant work rate treadmill task 
with clinically meaningful improvements in dyspnea and 
health status compared with pulmonary rehabilitation alone 
(Casaburi et al 2005). Effects were sustained for 3 months 
following rehabilitation (Casaburi et al 2005). Short acting 
beta2-agonists, inhaled steroids, and theophylline were 
allowed in the study, but not long acting beta2-agonists or 
short acting anticholinergics so patients could be seen as not 
optimally managed in the placebo group.
Adverse effects
Adverse effects of medications have to be balanced against 
positive effects. Side effects of anticholinergics, including 
dry mouth, glaucoma, and urinary retention are mediated 
principally by the M3 receptors. Tiotropium appears to be 
well tolerated, with dry mouth being the only signiﬁ  cant 
adverse event, which led to 1% of patients withdrawing from 
the study in the Casaburi and colleagues (2002) study.
Conclusions and place in therapy
In the past, the care, management, and treatment of COPD 
has not been optimal. Treatment has often followed asthma 
treatment, although the causes, disease process, management 
and treatments differ. COPD is increasingly seen as a separate 
disease so studies into speciﬁ  c treatments increase and our 
knowledge improves. From available evidence anticholinergic 
therapy is better than placebo and appears in some studies 
to be superior to the beta2-agonists. Whilst oxitropium and 
speciﬁ  cally ipratropium have shown beneﬁ  ts, tiotropium has an 
edge over its precursors in terms of its selectivity and clinical 
effects, speciﬁ  cally in terms of patients’ symptoms.
Although guidelines support long-acting bronchodilators 
if patients remain symptomatic after short-acting broncho-
dilators (NCCCC 2004), it may be that earlier use of these 
agents and speciﬁ  cally tiotropium may lead to objective 
and subjective improvements. Whilst there is evidence that 
anticholinergics may be the preferential treatment of choice 
over beta2-agonists (Rees 2002), increasingly the long acting 
bronchodilators are being tested together and there is some 
evidence of synergism (Di Marco et al 2006).
Clearly anticholinergics have been used in obstructive 
disease for many years and they still have a relevant and use-
ful place in therapy. Beneﬁ  ts now require further evaluation 
in clinical practice and the place of the therapies substantiated 
over the long term. Additionally patients enrolled in clinical 
trials, the level of severity of their disease, and exacerbation 
rates requires examination to ascertain if they are truly rep-
resentative of the patient groups we see in clinical practice. 
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